GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Tyra Biosciences Inc.
The stock price of Tyra Biosciences, an oncology biotech, reflects the potential of its platform for developing targeted therapies. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Oncology targeted therapy
Tyra Biosciences is a biotech company developing targeted therapies to combat drug-resistant cancers. We've categorized it as a "Targeted Oncology" company. The chart below shows how the market values companies working on next-generation oncology drugs.
Broad Market Index - GURU.Markets
Tyra Biosciences is a biotech company developing targeted therapies to combat drug-resistant cancer. Its innovativeness earns it a spot in the GURU.Markets index. The chart below compares its performance to the broader market.
Change in the price of a company, segment, and market as a whole per day
TYRA - Daily change in the company's share price Tyra Biosciences Inc.
Shares of Tyra Biosciences, a developer of targeted therapies, are exhibiting the extreme volatility typical of biotech. change_co tracks investor reactions to the publication of research data. This parameter is key for building high-risk asset valuation models on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology targeted therapy
Tyra Biosciences, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with TYRA's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Tyra is a biopharmaceutical company developing targeted therapies for cancer. Oncology is a highly volatile sector driven by clinical trial results. The chart below reflects average fluctuations in this industry, providing context for evaluating Tyra shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Tyra Biosciences Inc.
Tyra is a biotech company specializing in the development of targeted therapies for cancer treatment. Its shares are buoyed by anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Annual dynamics of market capitalization of the market segment - Oncology targeted therapy
Tyra Biosciences, Inc. is a biotech company developing targeted cancer therapies designed to overcome resistance to existing therapies. Its stock performance is entirely dependent on clinical trial results. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tyra Biosciences is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Tyra Biosciences Inc.
Sigma Lithium, a company developing a large lithium project in Brazil. The monthly fluctuations on the chart reflect lithium prices, as well as progress in ramping up production and signing contracts with customers, such as battery manufacturers.
Monthly dynamics of market capitalization of the market segment - Oncology targeted therapy
Tyra Biosciences develops targeted therapies for cancer, targeting mutations that cause resistance to treatment. The biotech sector, particularly oncology, is buzzing with anticipation of breakthroughs. The industry dynamics shown in the chart provide the backdrop against which Tyra strives to prove the effectiveness of its approach and carve out a niche in this vast market.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tyra Biosciences, Inc. is a biopharmaceutical company focused on developing targeted therapies for the treatment of cancers resistant to existing drugs. The company's future depends on the success of its clinical trials. The broader market chart serves only as a backdrop to understand how its scientific approach to overcoming drug resistance impacts its valuation.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Tyra Biosciences Inc.
Tyra Biosciences is a biotech company focused on targeted cancer therapy. Its weekly stock price is highly volatile, depending on news about research progress and early-stage clinical trial data.
Weekly dynamics of market capitalization of the market segment - Oncology targeted therapy
Tyra Biosciences is a biotech company focused on cancer treatment. Comparing its weekly performance to the broader biotech sector only highlights its uniqueness. The chart below shows how news about clinical trials of its targeted drugs drives its stock price movement independently of overall trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Tyra, a biotech company, live in a world of their own. Their performance is driven by clinical trial data. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
TYRA - Market capitalization of the company Tyra Biosciences Inc.
Tyra Biosciences' market capitalization chart tells the story of its development of next-generation targeted therapies to combat cancer. The company focuses on creating drugs that can overcome drug resistance. Its performance reflects investors' faith in its scientific approach and potential to solve one of the major challenges in oncology.
TYRA - Share of the company's market capitalization Tyra Biosciences Inc. within the market segment - Oncology targeted therapy
Tyra Biosciences is a biotech company developing targeted cancer therapies to overcome drug resistance. Its market share reflects the potential of its precision science platform. The chart below shows the market weighting of its approach to combating tumor evolution.
Market capitalization of the market segment - Oncology targeted therapy
Tyra Biosciences develops targeted therapies to combat drug resistance in oncology. The chart below shows the overall market capitalization of the oncology sector. It highlights one of the key challenges in modern cancer therapy and the importance of developing next-generation drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph represents the high-precision fight against drug resistance in oncology. Tyra Biosciences is developing drugs that can overcome mutations that make cancer resistant to therapy. Its capitalization line is a bet on this "smart" approach to treatment. It's a visualization of the next step in targeted therapy.
Book value capitalization of the company, segment and market as a whole
TYRA - Book value capitalization of the company Tyra Biosciences Inc.
Tyra Biosciences' book value is derived from its SNAP scientific platform for developing targeted therapies for cancer resistant to existing therapies, as well as its financial reserves. This represents cutting-edge scientific capital. The chart shows how the company accumulates and spends funds to develop next-generation oncology drugs.
TYRA - Share of the company's book capitalization Tyra Biosciences Inc. within the market segment - Oncology targeted therapy
Tyra Biosciences is a biotech company developing targeted therapies to fight cancer. Its strength lies in its scientific platform that enables it to overcome drug resistance. The chart shows that its value lies in innovation, not manufacturing capacity.
Market segment balance sheet capitalization - Oncology targeted therapy
Developing targeted therapies like Tyra's is a knowledge-intensive but relatively "easy" business at the R&D stage. Its value lies in its drug discovery platform. Compared to the capital-intensive pharmaceutical sector, the company's model doesn't require the ownership of large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
Tyra Biosciences' assets are not production lines, but a research platform and laboratories for developing targeted therapies capable of overcoming drug resistance in cancer treatment. The book value reflects the material foundation for this high-precision research. The chart illustrates the scale of this biotech company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Tyra Biosciences Inc.
Tyra Biosciences, a biotech company focused on overcoming drug resistance in oncology, is valued on the market at several times the value of its laboratories. Investors are paying for its rigorous scientific approach, which could offer hope to patients who have lost their effectiveness with existing drugs.
Market to book capitalization ratio in a market segment - Oncology targeted therapy
Tyra Biosciences is a biotech company developing targeted therapies to combat drug resistance in cancer. Its high valuation on this chart reflects investors' faith in its scientific approach to solving one of the key problems in oncology.
Market to book capitalization ratio for the market as a whole
Tyra Biosciences is a biotech company developing targeted cancer therapies designed to overcome drug resistance. Its scientific platform is aimed at creating "smarter" drugs. This metric reflects the premium the market is willing to pay for innovative approaches in oncology that can improve patient outcomes.
Debts of the company, segment and market as a whole
TYRA - Company debts Tyra Biosciences Inc.
Tyra Biosciences, a biotech company developing targeted cancer therapies, funds its high-tech research with raised capital. Debt instruments can be used to provide financial flexibility between funding rounds. This chart reflects the cost of innovation at the forefront of oncology.
Market segment debts - Oncology targeted therapy
Tyra Biosciences is a biotech company focused on developing targeted cancer therapies that can overcome drug resistance. This chart illustrates how the company, which is in early clinical trials, is funding its innovative scientific platform, which is typical for biotech startups working at the cutting edge of science.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Tyra Biosciences Inc.
Tyra Biosciences is a biotech company developing targeted therapies to combat drug-resistant cancers. Its SNAP platform enables the creation of highly specific drugs. This chart shows how the company uses debt to fund its innovative, but very expensive and time-consuming, oncology research.
Market segment debt to market segment book capitalization - Oncology targeted therapy
Tyra Biosciences is a biotech company developing targeted cancer therapies to overcome drug resistance. This is an important but challenging task. This chart shows how the company finances its research, relating its debt structure to the overall financial picture in the capital-intensive biotech sector.
Debt to book value of all companies in the market
Tyra Biosciences develops targeted therapies to combat cancer resistant to existing treatments. This is a cutting-edge but capital-intensive field of oncology. How heavily does the company rely on debt to finance its innovations? This graph of total debt in the economy helps assess the riskiness of its financial model.
P/E of the company, segment and market as a whole
P/E - Tyra Biosciences Inc.
Tyra Biosciences is a biotech company developing targeted cancer therapies designed to overcome drug resistance. This chart shows how investors rate its scientific approach. Its high valuation reflects the company's belief that its technology can help patients who have failed existing treatments.
P/E of the market segment - Oncology targeted therapy
Tyra Biosciences is a clinical-stage biotechnology company specializing in the development of targeted cancer therapies that overcome drug resistance. This chart shows the average market value for the sector, helping to understand how the market views Tyra's innovative approach to oncology.
P/E of the market as a whole
Tyra Biosciences is a biotech company developing targeted therapies to combat drug resistance in cancer. This is an important and complex issue. Does the company's valuation reflect a general interest in oncology, or is it a unique bet on its platform and ability to develop drugs for niche but critically important patient groups?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Tyra Biosciences Inc.
Tyra Biosciences is a biotech company developing targeted therapies for cancer resistant to existing therapies. This chart shows market expectations for the success of its scientific platform. Future profits depend on clinical trial results and the ability to develop next-generation drugs.
%20P%2FE%20Tyra%20Biosciences%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Tyra-Biosciences-Inc.&v=1772688348571 "Chart of the company's future (projected) P/E Tyra Biosciences Inc.")
Future (projected) P/E of the market segment - Oncology targeted therapy
Tyra Biosciences is a precision oncology company developing drugs to overcome resistance to targeted therapies. Its SNAP technology enables the creation of drugs against mutated cancer cells. The chart shows forecasts for the oncology sector, helping to assess how highly the market values Tyra's innovative approach and the potential of its platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-targeted-therapy&v=1772688348581 "Future (projected) P/E graph of the market segment - Oncology targeted therapy")
Future (projected) P/E of the market as a whole
Tyra Biosciences, Inc. is a biotech company developing targeted therapies to combat drug resistance in cancer. This is an important and complex scientific challenge. This graph of overall risk appetite shows how willing investors are to fund cutting-edge oncology research with a long-term horizon.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772688348590 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Tyra Biosciences Inc.
Tyra Biosciences is a precision oncology company developing targeted therapies to combat drug resistance. Being in early-stage research, its financial results reflect R&D expenses. The chart shows the cost of developing smart drugs to address complex challenges in cancer treatment.
Profit of companies in the market segment - Oncology targeted therapy
Tyra Biosciences is a biotech company developing targeted therapies to combat cancers resistant to existing treatments. This chart, which shows the company's profitability in the oncology sector, demonstrates the importance of combating drug resistance. Their SNAP platform is aimed at developing next-generation drugs that can overcome this serious problem.
Overall market profit
Tyra Biosciences is developing targeted therapies to combat drug resistance in cancer treatment. This is a critical issue in oncology. Funding for such cutting-edge research depends on the overall investment climate. Growing corporate profits, as shown in this chart, create an environment in which investors are more inclined to support innovative biotech companies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Tyra Biosciences Inc.
Tyra Biosciences is a biotech company developing targeted cancer therapies designed to overcome drug resistance. Its SNAP platform enables the creation of more precise drugs. This chart summarizes analyst opinions on the potential of their technology and progress in clinical trials to combat drug-resistant tumors.
%20profit%20of%20the%20company%20Tyra%20Biosciences%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Tyra-Biosciences-Inc.&v=1772688348648 "Graph of future (projected) profit of the company Tyra Biosciences Inc.")
Future (predicted) profit of companies in the market segment - Oncology targeted therapy
Tyra Biosciences is a biotech company developing targeted cancer therapies that overcome drug resistance. Its value lies in its SNAP platform. This chart for the oncology sector illustrates how highly the market perceives the need for new treatments for patients for whom existing therapies have failed.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-targeted-therapy&v=1772688348671 "Graph of future (predicted) profits of companies in a market segment - Oncology targeted therapy")
Future (predicted) profit of the market as a whole
Tyra Biosciences is a biotech company developing targeted cancer therapies. Its future depends on breakthroughs in the lab. However, the overall profit forecast, reflected in this chart, provides an investment backdrop. During periods of economic optimism, investors are more inclined to fund high-risk scientific projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772688348687 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Tyra Biosciences Inc.
Tyra Biosciences is a biotech company focused on developing targeted cancer therapies designed to overcome drug resistance. Despite the lack of revenue, this chart is crucial. It shows how investors view its innovative platform and future sales potential, betting on a breakthrough in oncology.
P/S market segment - Oncology targeted therapy
Tyra Biosciences uses its SNAP platform to develop targeted cancer therapies that overcome drug resistance. The company's valuation is based on the potential of this cutting-edge technology. This chart shows the average valuation in the sector, allowing investors to understand the high expectations for Tyra's innovative approach to developing next-generation cancer therapies.
P/S of the market as a whole
Tyra Biosciences is a biotech company developing targeted therapies for the treatment of drug-resistant cancers. The company strives to create drugs that work where others have failed. This chart, which reflects revenue estimates for traditional companies, highlights that Tyra's valuation is a bet on its ability to solve the most complex problems in oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Tyra Biosciences Inc.
Tyra Biosciences is a biotech company developing targeted therapies for cancer treatment aimed at overcoming drug resistance. Its SNAP platform enables the creation of precision drugs. This chart reflects investors' confidence in the potential of its technology to create a new generation of oncology drugs in the future.
%20P%2FS%20Tyra%20Biosciences%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Tyra-Biosciences-Inc.&v=1772688348756 "The graph of the company's future (projected) P/S Tyra Biosciences Inc.")
Future (projected) P/S of the market segment - Oncology targeted therapy
Tyra Biosciences is a biotech company using its SNAP platform to develop targeted therapies for oncology aimed at overcoming drug resistance. This chart shows the average estimated future sales in the oncology sector. It helps understand how the market views Tyra's innovative approach to creating next-generation drugs.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-targeted-therapy&v=1772688348761 "Future (projected) P/S market segment graph - Oncology targeted therapy")
Future (projected) P/S of the market as a whole
Tyra Biosciences develops targeted cancer therapies that overcome drug resistance. This chart illustrates overall market expectations. The company's innovative approach to combating drug resistance is a key challenge in modern oncology and fuels investor hopes for more durable treatments.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772688348793 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Tyra Biosciences Inc.
This chart shows the revenue of Tyra Biosciences, a clinical-stage biotech company developing targeted therapies to fight cancer. Its focus is on developing drugs that overcome drug resistance. Revenue at this stage is generated through partnerships, reflecting the scientific progress and potential of its developments.
Sales of companies in the market segment - Oncology targeted therapy
Tyra Biosciences is a biotechnology company developing precision cancer drugs that overcome resistance to existing therapies. This chart illustrates the growth of the targeted oncology market. The company's innovative platform enables the creation of a new generation of drugs that can significantly improve patient outcomes.
Overall market sales
Tyra Biosciences is a biotech company developing targeted therapies to combat drug resistance in cancer treatment. Its market capitalization depends on scientific progress. The overall economic situation, shown in this chart, influences investor willingness to fund cutting-edge and risky oncology research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Tyra Biosciences Inc.
Tyra Biosciences is a biotech company developing targeted cancer therapies with a focus on overcoming drug resistance. Its revenue forecast is based on expectations for the success of its R&D platform. The chart reflects analysts' confidence in the potential of its developments.
%20sales%20of%20the%20company%20Tyra%20Biosciences%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Tyra-Biosciences-Inc.&v=1772688348818 "Schedule of future (projected) sales of the company Tyra Biosciences Inc.")
Future (projected) sales of companies in the market segment - Oncology targeted therapy
Tyra Biosciences is a biotech company developing next-generation targeted therapies for cancer treatment. Its SNAP platform enables the creation of drugs that overcome drug resistance. This chart shows the outlook for the oncology market, where Tyra's approach could offer new solutions for patients for whom other therapies have failed.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-targeted-therapy&v=1772688348834 "Schedule of future (projected) sales of companies in the market segment - Oncology targeted therapy")
Future (projected) sales of the market as a whole
Tyra Biosciences develops targeted therapies to combat drug resistance in cancer treatment. This is a significant and complex problem in oncology. This chart reflects overall market sentiment, but for Tyra, the key driver is its scientific platform and ability to develop drugs that can help patients when other treatments fail.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772688348839 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Tyra Biosciences Inc.
Tyra Biosciences is a biotech company developing targeted drugs for cancer treatment. It focuses on overcoming drug resistance. Being in preclinical and early clinical trials, it incurs significant expenses. This chart shows its net losses—investments in developing the next generation of "smart" cancer drugs.
Market segment marginality - Oncology targeted therapy
Tyra Biosciences is a clinical-stage biotech company using its platform to develop targeted cancer therapies designed to overcome drug resistance. Profitability is a long-term goal. This chart reflects investment in their innovative scientific platform. Investors assess its potential to address a significant challenge in oncology.
Market marginality as a whole
Tyra Biosciences is a biotech company developing targeted therapies to fight cancer. They focus on creating drugs that can overcome drug resistance. This overall profitability curve is irrelevant to them. Their success depends on scientific breakthroughs and the ability of their platform to create effective next-generation drugs.
Employees in the company, segment and market as a whole
Number of employees in the company Tyra Biosciences Inc.
Tyra Biosciences is a biotech company developing targeted therapies to combat drug resistance in cancer. Its team of scientists uses a proprietary platform to create new molecules. The growth in this chart reflects progress in its R&D and the expansion of its development pipeline.
Share of the company's employees Tyra Biosciences Inc. within the market segment - Oncology targeted therapy
Tyra Biosciences develops targeted therapies to combat cancer, focusing on overcoming drug resistance. This chart shows the percentage of scientific talent the company attracts in this narrow field of oncology. The growth in this indicator reflects the progress of its research platform and the expansion of its team creating next-generation anticancer drugs.
Number of employees in the market segment - Oncology targeted therapy
Tyra Biosciences, Inc. is a precision oncology company focused on developing small-molecule therapies to overcome drug resistance in cancer. This chart shows the dynamics of employment in the cutting-edge field of targeted therapy. The growing number of researchers in this niche reflects one of the key challenges in modern oncology and the desire to create a new generation of more durable drugs.
Number of employees in the market as a whole
Tyra Biosciences is a biotechnology company developing targeted therapies to combat cancers that have become resistant to existing treatments. Its SNAP platform enables the creation of highly targeted drugs. This indicator reflects how Tyra's cutting-edge oncology research creates new hope for patients and jobs for scientists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Tyra Biosciences Inc. (TYRA)
Tyra Biosciences is a biotech company specializing in precision oncology. This chart represents a pure intellectual capital valuation. The market values its SNAP scientific platform's potential to create new treatments, not its staff. The chart shows the high future value investors are placing on this technology per scientist.
%20of%20the%20company%20Tyra%20Biosciences%20Inc.%20(TYRA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Tyra-Biosciences-Inc.-TYRA&v=1772688348995 "Chart of market capitalization per employee (in thousands of dollars) of the company Tyra Biosciences Inc. (TYRA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Tyra Biosciences is a biotech company developing targeted therapies for cancer treatment. It focuses on overcoming drug resistance. Its value is determined by its unique scientific platform. This chart shows the high valuation of its cutting-edge technologies and intellectual property per scientist.
%20by%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-targeted-therapy&v=1772688349016 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology targeted therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Tyra Biosciences is a biotech company developing targeted therapies for cancer treatment. The chart reflects its scientific potential. The company's entire value is derived from the hope of successful clinical trials. This indicator demonstrates the value the market places on the work of a small but highly qualified team of scientists.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772688349045 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Tyra Biosciences Inc. (TYRA)
Tyra Biosciences is a clinical-stage biotech company specializing in the development of targeted therapies for cancer treatment. They focus on overcoming drug resistance. This is R&D. This chart shows capital burn: the amount the company spends on each scientist during expensive clinical trials.
%20Chart%20Tyra%20Biosciences%20Inc.%20(TYRA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Tyra-Biosciences-Inc.-TYRA&v=1772688349063 "Company Profit Per Employee (in thousands of dollars) Chart Tyra Biosciences Inc. (TYRA)")
Profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Tyra Biosciences (TYRA) is a clinical-stage biotechnology company developing targeted therapies for the treatment of cancers resistant to existing therapies. This metric (loss per employee) reflects the high cost of R&D and the creation of new molecules.
%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-targeted-therapy&v=1772688349079 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Tyra Biosciences is a clinical-stage biotech company specializing in targeted cancer therapy. It's an R&D company and has no profit. This chart shows the company's capital burn rate: the operating loss per research team developing a new drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772688349081 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Tyra Biosciences Inc. (TYRA)
Tyra Biosciences is a biotech company developing targeted therapies to combat drug resistance in cancer. This chart reflects the initial stages of monetization of its SNAP platform. Growth in revenue per employee will likely be driven by partnerships with major pharmaceutical companies.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Tyra-Biosciences-Inc.-TYRA&v=1772688349098 "Sales chart per company employee Tyra Biosciences Inc. (TYRA)")
Sales per employee in the market segment - Oncology targeted therapy
Tyra Biosciences (TYRA) develops targeted cancer therapies designed to overcome drug resistance. This chart shows how productive their R&D team is. It measures revenue (from partnerships) per scientist, which is an indicator of the effectiveness of their scientific platform.
Sales per employee for the market as a whole
Tyra Biosciences (TYRA) is a clinical-stage biotech company developing targeted therapies for cancer. The company uses its SNAP platform to combat drug resistance. The company has no commercial revenue. This chart illustrates a typical R&D situation: its research staff generates data and patents, but not revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Tyra Biosciences Inc. (TYRA)
Tyra Biosciences, Inc. is a biotech company developing targeted therapies to combat drug resistance in cancer treatment. The bearish sentiment shown in this chart reflects investor bets that its approach to overcoming resistance will prove ineffective in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Tyra-Biosciences-Inc.-TYRA&v=1772688349138 "Short Shares Chart for the Company Tyra Biosciences Inc. (TYRA)")
Shares shorted by market segment - Oncology targeted therapy
Tyra Biosciences is a biotech company developing targeted cancer drugs (FGFR inhibitors). This indicator reflects skepticism. "Shorts" here represent a bet that their drugs will not prove effective or safe in clinical trials.
Shares shorted by the overall market
Tyra Biosciences is a biotech company developing targeted cancer therapies. Their goal is to combat drug resistance. It's a complex science. When fear rises on this chart, investors don't want to delve into the mechanisms of resistance. They see "biotech" and "losses" and hit the "sell" button.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Tyra Biosciences Inc. (TYRA)
Tyra Biosciences (TYRA) is a biotech company developing precision oncology drugs to overcome resistance to existing cancer treatments. This chart measures hype. It shows "overbought" (above 70) during positive R&D data or "oversold" (below 30) during periods of no news, which is typical for the biotech sector.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Tyra-Biosciences-Inc.-TYRA&v=1772688349274 "RSI 14 indicator chart for the company's stock Tyra Biosciences Inc. (TYRA)")
RSI 14 Market Segment - Oncology targeted therapy
Tyra (TYRA) is a biotech company developing precision therapies to combat cancer drug resistance. The RSI_14_Seg for "Oncology" (biotech) shows the overall sentiment. The chart helps us understand: is TYRA's volatility due to its R&D or is the entire sector overheated?
RSI 14 for the overall market
Tyra (TYRA) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TYRA (Tyra Biosciences Inc.)
Tyra Biosciences is using its SNAP platform to develop smart drugs for targeted oncology that can overcome drug resistance. This chart shows the analysts' average 12-month forecast, representing their collective bet on the early success of this innovative technology platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TYRA-Tyra-Biosciences-Inc.&v=1772688349387 "A chart showing analyst consensus forecasts for the expected stock price. TYRA (Tyra Biosciences Inc.)")
The difference between the consensus estimate and the actual stock price TYRA (Tyra Biosciences Inc.)
Tyra Biosciences is a clinical-stage biotech company focused on precision oncology. Its SNAP platform develops targeted drugs that attack cancer and combat drug resistance. This chart shows the difference between the consensus estimate and the price, reflecting analyst confidence in this R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TYRA-Tyra-Biosciences-Inc.&v=1772688349447 "A chart showing the difference between the consensus forecast and the actual stock price. TYRA (Tyra Biosciences Inc.)")
Analyst consensus forecast for stock prices by market segment - Oncology targeted therapy
Tyra Biosciences is a biotech company developing smart, targeted oncology drugs that can overcome drug resistance in tumors. This chart shows overall expectations for the targeted oncology sector, reflecting experts' confidence in the success of this "second-line" cancer therapy.
Analysts' consensus forecast for the overall market share price
Tyra Biosciences (TYRA) is an R&D biotech focused on precision oncology (targeted therapy). They're burning through cash. This chart, reflecting expert expectations, reflects their risk appetite. When the market is pessimistic, investors are unwilling to fund long-term scientific projects, even promising ones.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Tyra Biosciences Inc.
Tyra Biosciences is a biotech company developing smart drugs for targeted oncology. Their signature platform is SNAP, which creates drugs capable of overcoming drug resistance in tumors. This chart is a pure indicator of their platform. It likely aggregates their clinical trial data and market confidence in their technological approach.
AKIMA Market Segment Index - Oncology targeted therapy
Tyra (TYRA) is a clinical-stage biotech focused on precision oncology (cancer); the company uses its SNAP R&D platform to develop targeted therapies that overcome drug resistance. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this R&D platform (TYRA) differentiate it from the average pharma company?
The AKIM Index for the overall market
Tyra Biosciences is a precision oncology company developing drugs targeting tumor-derived gene resistance (FGFR). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this clinical-stage research compares to the broader economic trends affecting the healthcare sector.
